MINITÜB SLOVAKIA
Assisted reproduction systems for animal insemination and embryo transfer, also used in human fertility treatment
Highlights
- ProfitableFY2025 net profit €453k · RÚZ
About MINITÜB SLOVAKIA
Minitüb describes itself as a system supplier for assisted reproduction in animals. Its products and technologies cover artificial insemination, embryo transfer and related biotechniques, and the website states that they are also used in fertility treatment for humans.
The website names animal reproduction and fertility treatment as application areas, but does not describe its sales channels or pricing. The Slovak entity, MINITÜB SLOVAKIA spol. s r.o., is registered as a limited liability company in Čeľadice, Slovakia, and is a subsidiary of a foreign group.
The company was founded in 1996, according to the Slovak registry. The careers site lists work locations in Germany, the USA and Slovakia, and is published in German, English, Slovak and Spanish. Current open positions are listed on a separate jobs page.
Product: Technologies and products for artificial insemination, embryo transfer and assisted reproduction in animals and humans.
Financials
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | €11.4M | €10.7M | €10.6M | €9.7M | €9.9M |
| Growth | +6% | +1% | +9% | −2% | — |
| EBITDA | €1.3M | €1.3M | €1.3M | €1.2M | €1.3M |
| Operating profit | €742k | €708k | €807k | €474k | €861k |
| Net profit | €453k | €411k | €583k | €347k | €658k |
| Net margin | 4% | 3.8% | 5.5% | 3.6% | 6.6% |
| Personnel costs | €3.9M | €3.6M | €3.4M | €3.2M | €3.3M |
| Total assets | €9.8M | €9.9M | €9.3M | €7.1M | €6.3M |
| Cash | €991k | €788k | €817k | €722k | €480k |
| Liabilities | €4.9M | €5.5M | €5.3M | €3.7M | €3.3M |
| Equity | €4.8M | €4.4M | €4.0M | €3.4M | €3.1M |
As filed with RÚZ (Slovak register of financial statements). Each year links to its statement.
Jobs at MINITÜB SLOVAKIA
Leadership
- Rudolf Simmet · Konateľ (Managing director)Source: business register
- Thomas Schultze · Konateľ (Managing director)Source: business register
More biotech & pharma companies
MultiplexDX
Cancer diagnostics, molecular testing, and research services for healthcare and life-science organizationsGrowingNovo Nordisk Slovakia
Pharmaceutical company in Slovakia presenting prescription medicines and careers; Bratislava-based subsidiary of a foreign groupProfitableNOVYSIAN
Dietary supplements for mental health, digestive and respiratory conditions, aimed at patients and healthcare professionals in SlovakiaYoung companyOH SK
Private label development and certified manufacturer sourcing for medical and pharma brands in the EUYoung companyProfitableGrowingREGENMED
Contract in vitro toxicity, genotoxicity and tissue-engineering testing for pharma, chemical and cosmetics companiesProfitableREGES
Pharmaceutical and medical device distribution from manufacturers to pharmacies and healthcare facilitiesYoung companyGrowing
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- ElementorHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Forms
- Gravity FormsHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.
